2025-04-04 - Analysis Report
## Johnson & Johnson (JNJ) Stock Performance Review

**0. Executive Summary:**

Johnson & Johnson (JNJ), a leading healthcare company, has underperformed the S&P 500 (VOO) significantly over the analyzed period. While showing relatively stable profitability, its recent performance lags behind the market, warranting further investigation into potential catalysts for future growth.


**1. Performance Comparison & Alpha/Beta Analysis:**

Johnson & Johnson (JNJ) has shown a cumulative return of 33.08%, while the S&P 500 (VOO) achieved 85.44%. This represents a considerable underperformance of -52.4%, placing it at the 31.3th percentile of its historical range against the S&P 500 (based on provided min/max range).

The provided Alpha/Beta analysis reveals mixed results. While CAGR varies across periods, the Alpha consistently hovers around 0, indicating JNJ's returns are mostly in line with market expectations, except for periods where it significantly underperforms. The high Beta (generally above 0.2) suggests high sensitivity to market fluctuations.  Market capitalization (Cap(B)) remains consistently high, but not necessarily reflective of the underperformance relative to the S&P 500.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 24.0% | 5.5% | 6.0% | -0.2 | 275.3 |
| 2016-2018  | 9.0% | 12.2% | 2.0% | -0.5 | 261.2 |
| 2017-2019  | 18.0% | 12.2% | -1.0% | 0.2 | 303.6 |
| 2018-2020  | 15.0% | 12.2% | -19.0% | 0.2 | 336.4 |
| 2019-2021  | 29.0% | 9.1% | -44.0% | 0.2 | 374.9 |
| 2020-2022  | 16.0% | 49.1% | 5.0% | 0.2 | 397.3 |
| 2021-2023  | -12.0% | 49.1% | -30.0% | 0.4 | 363.2 |
| 2022-2024  | -26.0% | 49.1% | -48.0% | 0.3 | 345.7 |
| 2023-2025  | 0.0% | 49.4% | -37.0% | 0.2 | 385.1 |


**2. Recent Price Movement:**

* **Closing Price:** $159.82
* **5-Day Moving Average:** $159.60
* **20-Day Moving Average:** $162.64
* **60-Day Moving Average:** $156.54

The price is currently below both its 20-day and 60-day moving averages, suggesting a potential bearish trend.  The 5-day average is close to the current price, indicating some recent stabilization.  The price shows a recent increase of $2.87 compared to the previous close, indicating a mild short-term upward movement.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.432 (Medium Risk)
* **RSI:** 45.01 (Near neutral; neither overbought nor oversold)
* **PPO:** -0.656 (Negative, suggesting bearish momentum)
* **20-Day Relative Divergence Change:** +4.0 (Short-term upward trend)
* **Expected Return:** -53.8% (This is significantly negative and needs further clarification on its calculation method and assumptions, especially considering the negative alpha values in the table above. A -53.8% expected return is alarming and requires more scrutiny)

The recent price increase of $2.87 reflects a small, positive change and does not qualify as a significant “spike” or “dip”.


**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue       |
|------------|-------|----------------|
| 2024-10-23 | $1.12 | $22.47 Billion |
| 2024-07-25 | $1.95 | $22.45 Billion |
| 2024-05-01 | $1.35 | $21.38 Billion |
| 2024-02-16 | $1.68 | $21.39 Billion |
| 2023-10-27 | $10.32| $21.35 Billion |

There is a significant outlier in EPS for 2023-10-27. This requires further investigation to determine if this is a one-time event (e.g., a large one-off item) or indicative of a larger trend.  Revenue remains relatively consistent across the quarters. The fluctuation in EPS needs clarification.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-12-31 | $22.52B    | 68.35%        |
| 2024-09-30 | $22.47B    | 69.01%        |
| 2024-06-30 | $22.45B    | 69.40%        |
| 2024-03-31 | $21.38B    | 69.55%        |
| 2023-12-31 | $21.39B    | 68.23%        |

Revenue remains relatively stable, with slight fluctuations.  Profit margins are consistently high and show minor variations.

**Capital and Profitability:**

| Quarter | Equity      | ROE           |
|---------|-------------|---------------|
| 2024-12-31 | $71.49B    | 4.80%         |
| 2024-09-30 | $70.16B    | 3.84%         |
| 2024-06-30 | $71.54B    | 6.55%         |
| 2024-03-31 | $70.02B    | 4.65%         |
| 2023-12-31 | $68.77B    | 5.89%         |

Equity shows minor fluctuations. ROE fluctuates, but remains relatively stable.  These numbers provide a picture of reasonable financial health.


**6. Overall Analysis:**

JNJ shows consistent revenue and high profit margins, indicating solid financial health. However, its significant underperformance against the S&P 500, reflected in a negative alpha and a substantially lower cumulative return, is a major concern. The negative expected return (-53.8%) is extremely concerning and needs further investigation for its calculation method and underlying assumptions. The fluctuating EPS and the unexplained outlier in the October 2023 earnings require a thorough examination.  Before considering a long-term investment,  a deeper dive into the reasons for the underperformance relative to the market is necessary.  Factors such as competitive pressures, regulatory changes, and potential shifts in market sentiment should be carefully considered.  The high Beta suggests JNJ will be heavily affected by market downturns.  Considering the data provided, a long-term investment (2+ years) in JNJ needs further careful analysis before undertaking.
